Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that the latest version of Genedata Expressionist for Mass Spectrometry (MS) will be showcased at the 62nd ASMS Conference on Mass Spectrometry and Allied Topics. Developed in collaboration with leading mass spectrometry labs, the enterprise software platform reads data from all major mass spectrometry instruments as well as automates and standardizes complex workflows in biopharmaceutical R&D. With a scalable architecture that enables processing of huge experimental data sets, the system reduces data analysis times by factors of ten or more to accelerate the identification and quantification of critical quality attributes of biopharmaceuticals.
Genedata will demonstrate Genedata Expressionist for MS at Booth 57 at the 2014 ASMS Conference (Baltimore Convention Center; June 15-19, 2014).
Vendor-agnostic Solution Standardizes Characterization of Biopharmaceuticals
Today, characterization of biopharmaceuticals using mass spectrometry is a standard process within biopharmaceutical discovery and development. While the experimental process using mass spectrometry instruments is fully automated, the analysis of MS data remains often a manual process. Genedata Expressionist for MS allows scientists to quickly and easily deliver on even the most complex and data rich characterization projects. The system covers the entire data analysis process, from raw data import over data refinement and analysis to reporting.
The software, which reads data formats from all common MS instruments, can be used as an integration platform to standardize mass spectrometry data analysis during all R&D steps. User authentication, authorization, and rigorous documentation of all processing steps ensure the system is ready for deployment in a quality-compliant environment. It is regularly used in projects that focus on the identification of impurities, assessment of post translational modifications (PTMs), and quality control of protein batches. Genedata Expressionist for MS specifically supports the analysis of intact masses, protein sequence variants, N- and C-terminals, glycopeptides, released glycans, and disulphide bonds.
“With Genedata Expressionist for MS we raise the bar on the analysis of mass spectrometry data and set new standards for the efficient characterization of biopharmaceuticals,” said Dr. Othmar Pfannes, CEO of Genedata. “In close collaboration with major biopharmaceutical companies we are committed to advancing Genedata Expressionist as the vendor-agnostic platform of choice for the quality assessment of biopharmaceuticals and making key processes in biopharmaceutical R&D as efficient as possible.”
Genedata Expressionist for MS Demos
Poe Hospitality Suite
June 16 – 18: 8:00pm-11:00pm
Poster Presentation # 661
June 17: 10:30am – 2:30pm
“Complementary LC- and GC-Mass Spectrometry Techniques Provide Broader Coverage of the Metabolome”
Baljit Ubhi; Jeff Patrick; Joe Shambaugh
Poster Presentation # 50
June 18: 10:30am – 2:30pm
“Software Tools to Accelerate Peptide Mapping and Related Analysis for Characterizing Biotherapeutics”
Joe Shambaugh; Alessio Ceroni; Arnd Brandenburg; Jens Hoefkens; Peter Haberl
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US.
Follow Us on LinkedIn
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.